Which has better earnings & valuation, CODX or NEPH?

Nephros has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Co-Diagnostics $620K 14.49 -$46.90M -$15.77 N/A Nephros $19.12M 2.04 $1.19M $0.07 51.30

Is CODX or NEPH more profitable?

Nephros has a net margin of 4.06% compared to Co-Diagnostics' net margin of -6,760.63%. Nephros' return on equity of 7.66% beat Co-Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Co-Diagnostics -6,760.63% -164.92% -141.15% Nephros 4.06% 7.66% 5.86%

Does the media favor CODX or NEPH?

In the previous week, Co-Diagnostics and Co-Diagnostics both had 2 articles in the media. Co-Diagnostics' average media sentiment score of 0.94 equaled Nephros'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Co-Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nephros 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate NTRB or CODX?

Co-Diagnostics has a consensus price target of $67.50, suggesting a potential upside of 2,672.07%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Co-Diagnostics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is NTRB or CODX more profitable?

Nutriband has a net margin of -448.25% compared to Co-Diagnostics' net margin of -6,760.63%. Nutriband's return on equity of -112.64% beat Co-Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Nutriband -448.25% -112.64% -97.86% Co-Diagnostics -6,760.63% -164.92% -141.15%

Which has stronger earnings & valuation, CODX or NSPR?

InspireMD has higher revenue and earnings than Co-Diagnostics. InspireMD is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Co-Diagnostics $620K 14.49 -$46.90M -$15.77 N/A InspireMD $10.85M 3.07 -$19.92M -$0.73 N/A

Is CODX or NSPR more profitable?

InspireMD has a net margin of -413.96% compared to Co-Diagnostics' net margin of -6,760.63%. InspireMD's return on equity of -69.42% beat Co-Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Co-Diagnostics -6,760.63% -164.92% -141.15% InspireMD -413.96% -69.42% -57.68%

Does the media favor CODX or NSPR?

In the previous week, Co-Diagnostics had 1 more articles in the media than InspireMD. MarketBeat recorded 2 mentions for Co-Diagnostics and 1 mentions for InspireMD. Co-Diagnostics' average media sentiment score of 0.94 beat InspireMD's score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Co-Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InspireMD 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PETV or CODX?

Co-Diagnostics has a consensus price target of $67.50, suggesting a potential upside of 2,672.07%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe Co-Diagnostics is more favorable than PetVivo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Co-Diagnostics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, PETV or CODX?

PetVivo has higher revenue and earnings than Co-Diagnostics. PetVivo is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PetVivo $1.05M 26.60 -$10.95M -$0.38 N/A Co-Diagnostics $620K 14.49 -$46.90M -$15.77 N/A

Is PETV or CODX more profitable?

PetVivo has a net margin of -902.82% compared to Co-Diagnostics' net margin of -6,760.63%. Co-Diagnostics' return on equity of -164.92% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets PetVivo -902.82% -4,813.07% -281.78% Co-Diagnostics -6,760.63% -164.92% -141.15%

Does the media favor PETV or CODX?

In the previous week, PetVivo and PetVivo both had 2 articles in the media. Co-Diagnostics' average media sentiment score of 0.94 beat PetVivo's score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PetVivo 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Co-Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MLSS or CODX?

In the previous week, Milestone Scientific had 1 more articles in the media than Co-Diagnostics. MarketBeat recorded 3 mentions for Milestone Scientific and 2 mentions for Co-Diagnostics. Co-Diagnostics' average media sentiment score of 0.94 beat Milestone Scientific's score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Scientific 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Co-Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Co-Diagnostics (CODX) Competitors

$2.37 -0.13 (-5.02%)

As of 01:30 PM Eastern

Compare

CODX vs. NEPH, NTRB, NSPR, PETV, and MLSS

Should you buy Co-Diagnostics stock or one of its competitors? MarketBeat compares Co-Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Co-Diagnostics include Nephros (NEPH), Nutriband (NTRB), InspireMD (NSPR), PetVivo (PETV), and Milestone Scientific (MLSS). These companies are all part of the "medical equipment" industry.

How does Co-Diagnostics compare to Nephros?

Co-Diagnostics (NASDAQ:CODX) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

In the previous week, Co-Diagnostics and Co-Diagnostics both had 2 articles in the media. Co-Diagnostics' average media sentiment score of 0.94 equaled Nephros'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nephros	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Co-Diagnostics presently has a consensus target price of $67.50, suggesting a potential upside of 2,672.07%. Nephros has a consensus target price of $6.00, suggesting a potential upside of 67.08%. Given Co-Diagnostics' higher probable upside, equities analysts plainly believe Co-Diagnostics is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nephros has a net margin of 4.06% compared to Co-Diagnostics' net margin of -6,760.63%. Nephros' return on equity of 7.66% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%
Nephros	4.06%	7.66%	5.86%

Co-Diagnostics has a beta of 2.84, indicating that its stock price is 184% more volatile than the broader market. Comparatively, Nephros has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

15.0% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 5.4% of Co-Diagnostics shares are owned by company insiders. Comparatively, 6.7% of Nephros shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Nephros has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$620K	14.49	-$46.90M	-$15.77	N/A
Nephros	$19.12M	2.04	$1.19M	$0.07	51.30

Summary

Nephros beats Co-Diagnostics on 10 of the 13 factors compared between the two stocks.

How does Co-Diagnostics compare to Nutriband?

Nutriband (NASDAQ:NTRB) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

In the previous week, Co-Diagnostics had 1 more articles in the media than Nutriband. MarketBeat recorded 2 mentions for Co-Diagnostics and 1 mentions for Nutriband. Nutriband's average media sentiment score of 1.89 beat Co-Diagnostics' score of 0.94 indicating that Nutriband is being referred to more favorably in the media.

Company	Overall Sentiment
Nutriband	Very Positive
Co-Diagnostics	Positive

Nutriband has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.84, meaning that its stock price is 184% more volatile than the broader market.

Nutriband has a net margin of -448.25% compared to Co-Diagnostics' net margin of -6,760.63%. Nutriband's return on equity of -112.64% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-448.25%	-112.64%	-97.86%
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%

19.7% of Nutriband shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 52.2% of Nutriband shares are owned by insiders. Comparatively, 5.4% of Co-Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Co-Diagnostics has a consensus price target of $67.50, suggesting a potential upside of 2,672.07%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nutriband has higher revenue and earnings than Co-Diagnostics. Nutriband is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$1.80M	20.53	-$8.23M	-$2.58	N/A
Co-Diagnostics	$620K	14.49	-$46.90M	-$15.77	N/A

Summary

Nutriband beats Co-Diagnostics on 10 of the 16 factors compared between the two stocks.

How does Co-Diagnostics compare to InspireMD?

Co-Diagnostics (NASDAQ:CODX) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

InspireMD has higher revenue and earnings than Co-Diagnostics. InspireMD is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$620K	14.49	-$46.90M	-$15.77	N/A
InspireMD	$10.85M	3.07	-$19.92M	-$0.73	N/A

15.0% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 5.4% of Co-Diagnostics shares are owned by company insiders. Comparatively, 34.1% of InspireMD shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Co-Diagnostics had 1 more articles in the media than InspireMD. MarketBeat recorded 2 mentions for Co-Diagnostics and 1 mentions for InspireMD. Co-Diagnostics' average media sentiment score of 0.94 beat InspireMD's score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InspireMD	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Co-Diagnostics presently has a consensus price target of $67.50, indicating a potential upside of 2,672.07%. InspireMD has a consensus price target of $4.50, indicating a potential upside of 532.91%. Given Co-Diagnostics' higher possible upside, equities research analysts clearly believe Co-Diagnostics is more favorable than InspireMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Co-Diagnostics has a beta of 2.84, suggesting that its share price is 184% more volatile than the broader market. Comparatively, InspireMD has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

InspireMD has a net margin of -413.96% compared to Co-Diagnostics' net margin of -6,760.63%. InspireMD's return on equity of -69.42% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%
InspireMD	-413.96%	-69.42%	-57.68%

Summary

InspireMD beats Co-Diagnostics on 10 of the 16 factors compared between the two stocks.

How does Co-Diagnostics compare to PetVivo?

PetVivo (NASDAQ:PETV) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Co-Diagnostics has a consensus price target of $67.50, suggesting a potential upside of 2,672.07%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe Co-Diagnostics is more favorable than PetVivo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

24.5% of PetVivo shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 10.8% of PetVivo shares are held by insiders. Comparatively, 5.4% of Co-Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

PetVivo has a net margin of -902.82% compared to Co-Diagnostics' net margin of -6,760.63%. Co-Diagnostics' return on equity of -164.92% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PetVivo	-902.82%	-4,813.07%	-281.78%
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%

PetVivo has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.84, meaning that its stock price is 184% more volatile than the broader market.

PetVivo has higher revenue and earnings than Co-Diagnostics. PetVivo is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PetVivo	$1.05M	26.60	-$10.95M	-$0.38	N/A
Co-Diagnostics	$620K	14.49	-$46.90M	-$15.77	N/A

In the previous week, PetVivo and PetVivo both had 2 articles in the media. Co-Diagnostics' average media sentiment score of 0.94 beat PetVivo's score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PetVivo	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Co-Diagnostics beats PetVivo on 8 of the 15 factors compared between the two stocks.

How does Co-Diagnostics compare to Milestone Scientific?

Milestone Scientific (NYSE:MLSS) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

Milestone Scientific has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.84, suggesting that its stock price is 184% more volatile than the broader market.

Milestone Scientific presently has a consensus target price of $1.00, indicating a potential upside of 127.79%. Co-Diagnostics has a consensus target price of $67.50, indicating a potential upside of 2,672.07%. Given Co-Diagnostics' higher possible upside, analysts clearly believe Co-Diagnostics is more favorable than Milestone Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Scientific	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

5.8% of Milestone Scientific shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 9.2% of Milestone Scientific shares are held by company insiders. Comparatively, 5.4% of Co-Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Milestone Scientific had 1 more articles in the media than Co-Diagnostics. MarketBeat recorded 3 mentions for Milestone Scientific and 2 mentions for Co-Diagnostics. Co-Diagnostics' average media sentiment score of 0.94 beat Milestone Scientific's score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Milestone Scientific	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Milestone Scientific has higher revenue and earnings than Co-Diagnostics. Milestone Scientific is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Scientific	$8.90M	4.36	-$6.93M	-$0.05	N/A
Co-Diagnostics	$620K	14.49	-$46.90M	-$15.77	N/A

Milestone Scientific has a net margin of -52.01% compared to Co-Diagnostics' net margin of -6,760.63%. Milestone Scientific's return on equity of -60.26% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Scientific	-52.01%	-60.26%	-40.23%
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%

Summary

Milestone Scientific beats Co-Diagnostics on 9 of the 15 factors compared between the two stocks.

Get Co-Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CODX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CODX vs. The Competition

Export

Metric	Co-Diagnostics	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.95M	$9.50B	$6.87B	$12.58B
Dividend Yield	N/A	1.62%	2.68%	9.45%
P/E Ratio	-0.15	25.41	27.21	24.30
Price / Sales	14.49	26.32	516.66	87.93
Price / Cash	N/A	113.37	48.63	60.00
Price / Book	0.27	6.19	10.81	6.27
Net Income	-$46.90M	$177.20M	$3.59B	$331.55M
7 Day Performance	-7.77%	0.15%	-2.12%	-1.53%
1 Month Performance	-36.59%	8.71%	3.24%	-0.59%
1 Year Performance	-69.04%	14.37%	26.02%	18.83%

Co-Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CODX Co-Diagnostics	1.9958 of 5 stars	$2.37 -5.0%	$67.50 +2,754.1%	-68.9%	$8.77M	$620K	N/A	100	News Coverage Gap Down
NEPH Nephros	2.1502 of 5 stars	$3.41 -3.9%	$6.00 +76.0%	+3.1%	$37.03M	$18.79M	48.72	30
NTRB Nutriband	0.9759 of 5 stars	$3.03 -3.5%	N/A	-62.3%	$36.85M	$2.04M	N/A	10	Positive News
NSPR InspireMD	3.3318 of 5 stars	$0.72 +1.6%	$4.50 +526.9%	-68.7%	$33.62M	$10.85M	N/A	50	News Coverage
PETV PetVivo	N/A	$0.82 +3.1%	N/A	-5.6%	$31M	$1.05M	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CODX) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Co-Diagnostics (CODX) Competitors

CODX vs. NEPH, NTRB, NSPR, PETV, and MLSS

How does Co-Diagnostics compare to Nephros?

Summary

How does Co-Diagnostics compare to Nutriband?

Summary

How does Co-Diagnostics compare to InspireMD?

Summary

How does Co-Diagnostics compare to PetVivo?

Summary

How does Co-Diagnostics compare to Milestone Scientific?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CODX vs. The Competition

Co-Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Co-Diagnostics (CODX) Competitors

CODX vs. NEPH, NTRB, NSPR, PETV, and MLSS

How does Co-Diagnostics compare to Nephros?

Does the media favor CODX or NEPH?

Do analysts rate CODX or NEPH?

Is CODX or NEPH more profitable?

Which has more risk and volatility, CODX or NEPH?

Do insiders and institutionals hold more shares of CODX or NEPH?

Which has better earnings & valuation, CODX or NEPH?

Summary

How does Co-Diagnostics compare to Nutriband?

Does the media prefer NTRB or CODX?

Which has more risk & volatility, NTRB or CODX?

Is NTRB or CODX more profitable?

Do insiders & institutionals have more ownership in NTRB or CODX?

Do analysts rate NTRB or CODX?

Which has stronger valuation & earnings, NTRB or CODX?

Summary

How does Co-Diagnostics compare to InspireMD?

Which has stronger earnings & valuation, CODX or NSPR?

Do insiders & institutionals believe in CODX or NSPR?

Does the media favor CODX or NSPR?

Do analysts prefer CODX or NSPR?

Which has more volatility & risk, CODX or NSPR?

Is CODX or NSPR more profitable?

Summary

How does Co-Diagnostics compare to PetVivo?

Do analysts rate PETV or CODX?

Do insiders and institutionals have more ownership in PETV or CODX?

Is PETV or CODX more profitable?

Which has more volatility & risk, PETV or CODX?

Which has better valuation & earnings, PETV or CODX?

Does the media favor PETV or CODX?

Summary

How does Co-Diagnostics compare to Milestone Scientific?

Which has more volatility and risk, MLSS or CODX?

Do analysts recommend MLSS or CODX?

Do insiders & institutionals have more ownership in MLSS or CODX?

Does the media refer more to MLSS or CODX?

Which has stronger earnings and valuation, MLSS or CODX?

Is MLSS or CODX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CODX vs. The Competition

Co-Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools